Increasing incidence of candidaemia and shifting epidemiology in favor of Candida non-albicans in a 9-year period (2009–2017) in a university Greek hospital
- 196 Downloads
The aim of the present study was to analyze candidaemia’s epidemiology (incidence, species distribution, and susceptibility rates) and antifungal consumption during a 9-year period.
All candidaemias recorded at The University General Hospital of Patras, Greece, between 2009 and 2017 were included. Candida isolates were identified using the germ tube test, API 20C AUX System, and/or Vitek-2 YST card. Antifungal susceptibility was determined by the gradient method according to CLSI.
During the study period, 505 episodes of candidaemia were observed with an overall incidence of 1.5 episodes per 1000 hospital admissions (1.1 episodes in 2009 to 1.9 in 2017: P 0.038, r 0.694). C. albicans was the leading cause (200 cases; 39.6%), followed by C. parapsilosis (185; 36.6%), C. glabrata (56; 11.1%), C. tropicalis (50; 9.9%), C. krusei (8; 0.2%), C. lusitaniae (5; < 0.1%), and C. guilliermondii (1; < 0.1%). Overall resistance to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin (according to CLSI) were 11.6%, 4.1%, 2.0%, 6.0%, and 0.8%, respectively. The overall consumption of antifungal drugs was stable, with a significant reduction of fluconazole’s use in favor of echinocandins.
An increase in the incidence of candidaemia and a predominance of Candida non-albicans due to decreasing use of fluconazole in favor of more potent antifungals, such as echinocandins, are reported in this study.
KeywordsCandidaemia Echinocandins Fluconazole Antifungal consumption
This study was supported by funds of the Department of Microbiology, School of Medicine, University of Patras.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
The study was approved by the Bioethics’ Committee of the UGHP (no. 3324).
- 1.European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013.Google Scholar
- 16.Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement, M27-S4. Wayne: CLSI; 2012.Google Scholar
- 17.WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2018. Oslo. 2017. https://www.whocc.no/filearchive/publications/guidelines.pdf. Accessed 29 Jun 2018.
- 30.Arendrup MC, Pfaller MA, Danish Fungaemia Study G. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother. 2012;56:3965–8.CrossRefGoogle Scholar